- 询价
- AntibodySystem
- DHJ41099
- France
- 2025年07月12日
- Research Grade Biosimilar
- Human
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
AJE 润色服务限时 8 折起，权威机构信任 15+ 年Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
Enfortumab vedotin-ejfv (ADC)
- 抗体英文名：
Enfortumab vedotin-ejfv (ADC)
- 浓度：
1 mg/ml
- 应用范围：
Research Grade Biosimilar
- 适应物种：
Human
- 保质期：
1 year
- 级别：
科研级
- 库存：
999
- 供应商：
AntibodySystem
- 克隆性：
Monoclonal
- 保存条件：
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
- 形态：
Liquid
- 规格：
100ug
| 描述 | Enfortumab vedotin-ejfv is an ADC consisting of a Nectin-4-directed antibody and Monomethyl auristatin E (MMAE) , suitable for adult patients with locally advanced or metastatic urothelial carcinoma, or who have received programmed cell death protein 1 (PD-1) inhibitor or programmed cell death ligand 1 (PD-L1) inhibitor therapy or neoadjuvant/adjuvant platinum-based chemotherapy for locally advanced or metastatic cancer. |
| 种属反应性 | Human |
| 状态 | Liquid |
| 浓度 | 1 mg/ml |
| 纯度 | >90% as determined by SEC. |
| 克隆类型 | Monoclonal |
| 应用 | Research Grade Biosimilar |
| 靶标 | LNIR, NECTIN4, PRR4 receptor-related protein 4, Nectin cell adhesion molecule 4, Ig superfamily receptor LNIR, Nectin-4, PVRL4 |
| 纯化方式 | Purified by Ion Exchange Chromatography. |
| 内毒素水平 | Please contact with the lab for this information. |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| 别名 | Padcev, ASG-22ME |
| 克隆号 | Enfortumab vedotin-ejfv |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
Our products are designed for various research areas, supporting studies on 48 types of viruses, superbugs, parasites, cancer, Alzheimer's disease, Parkinson's disease, allergic responses, immune suppression, and immune activation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Nectin-4 ADC成功之后，NECTIN家族还有哪些“宝藏成员”？
，随后研究发现，其在多种肿瘤组织中出现异常表达，包括尿路上皮癌、乳腺癌、肺癌以及胰腺癌等 [10]。 相比正常成人组织，部分肿瘤细胞中Nectin-4表达明显升高，同时其位于细胞表面的特点使其具有较好的抗体可及性。这些特征使Nectin-4成为抗体药物开发的重要候选靶点。 目前最具代表性的应用是靶向Nectin-4的抗体偶联药物（antibody-drug conjugate, ADC）——Enfortumab vedotin。该药物利用抗Nectin-4抗体识别肿瘤细胞表面的Nectin
AntibodyDrug Conjugate (ADC) Clinical Pipeline: A Review
of improved compounds which are now in clinical trials. Brentuximab vedotin (Adcetris� ), an anti-CD30 antibody conjugated to a potent microtubule inhibitor for the treatment of Hodgkin’s lymphoma and anaplastic large cell lymphomas, is the only marketed ADC
技术资料暂无技术资料 索取技术资料
